Kentucky House Bill 249 (Prior Session Legislation)

---

Spectrum: Bipartisan Bill
Status: Introduced on January 13 2020 - 25% progression, died in committee
Action: 2020-01-21 - posted in committee
Pending: House Health and Family Services Committee
Text: Latest bill text (Introduced) [PDF]

Create various new sections of KRS Chapter 315 to define terms; to require the Cabinet for Health and Family Services to annually compile lists of certain prescription drugs deemed to be essential to treating diabetes; to require drug manufacturers to annually report to the cabinet certain information related to the cost of manufacturing and marketing such drugs and factors that contributed to any price increase; require pharmacy benefit managers to annually report to the cabinet certain information related to prescription drug rebates for such drugs; to require the cabinet to annually submit to the Legislative Research Commission a report that summarizes the information provided to the cabinet by manufacturers and pharmacy benefit managers; to exempt information and data reported by manufacturers and pharmacy benefit managers to the cabinet from disclosure pursuant to KRS 61.870 to 61.884; to require the cabinet to promulgate administrative regulations; amend KRS 315.990 to establish a penalty for failure to report; amend KRS 304.17A-164 to restrict cost-sharing amounts charged by insurers and pharmacy benefit managers; to prohibit insurers and pharmacy benefit managers from restricting a pharmacist's ability to inform patients about and to sell less expensive alternative drugs; amend KRS 304.17A-505 and 304.17C-030 to require disclosure of information related to drug formularies; to create various new sections of KRS Chapter 367 to define terms; to prohibit manufacturers and wholesalers of off-patent or generic prescription drugs from engaging in unrestricted price increases; to require the secretary of the Cabinet for Health and Family Services to report certain price increases to the Attorney General; to establish that certain price increases for off-patent or generic drugs constitute a violation of KRS 367.170; to establish penalties; and certain sections EFFECTIVE January 1, 2021.

AN ACT relating to prescription drugs.

Rep. Danny Bentley [R]	Rep. Tina Bojanowski [D]	Rep. Randy Bridges [R]	Rep. Deanna Frazier Gordon [R]
Rep. Kim King [R]	Rep. Ed Massey [R]	Rep. Patti Minter [D]	Rep. Phillip Pratt [R]
Rep. Maria Sorolis [D]	Rep. Cherlynn Stevenson [D]	Rep. Russell Webber [R]	Rep. Susan Westrom [D]

Date	Chamber	Action
2020-01-21	House	posted in committee
2020-01-15	House	to Health and Family Services (H)
2020-01-13	House	introduced in House

Type	Source
Summary	https://apps.legislature.ky.gov/record/20RS/hb249.html
Text	https://apps.legislature.ky.gov/recorddocuments/bill/20RS/hb249/orig_bill.pdf